Join Now

Author Archives: Press Release

Canyon Labs Announces Strategic Acquisition of iuvo BioScience’s Lab Services and Consulting Businesses to Expand End-to-End Development Solutions

Transaction positions iuvo BioScience for continued growth as an industry leader in ophthalmic clinical research

Posted in BioUtah News | Tagged | Comments Off on Canyon Labs Announces Strategic Acquisition of iuvo BioScience’s Lab Services and Consulting Businesses to Expand End-to-End Development Solutions

Denali Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted to Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II)

Denali expects to submit a Biologics License Application for tividenofusp alfa in early 2025 for regulatory review under the accelerated approval pathway

Posted in BioUtah News | Tagged | Comments Off on Denali Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted to Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II)

Recursion Announces Two Key Investigational Oncology Drugs Advancing to Clinical Trials, Targeting High Unmet Needs in Hematologic Malignancies, Small-Cell Lung Cancer, & More

Recursion Announces Two Key Investigational Oncology Drugs Advancing to Clinical Trials, Targeting High Unmet Needs in Hematologic Malignancies, Small-Cell Lung Cancer, & More

Posted in BioUtah News | Tagged | Comments Off on Recursion Announces Two Key Investigational Oncology Drugs Advancing to Clinical Trials, Targeting High Unmet Needs in Hematologic Malignancies, Small-Cell Lung Cancer, & More

MD Anderson and Myriad Genetics form strategic alliance to evaluate clinical utility of Myriad’s molecular residual disease assay

MD Anderson and Myriad Genetics form strategic alliance to evaluate clinical utility of Myriad’s molecular residual disease assay

Posted in BioUtah News | Tagged | Comments Off on MD Anderson and Myriad Genetics form strategic alliance to evaluate clinical utility of Myriad’s molecular residual disease assay

M42’s IROS and Halia Therapeutics launch clinical study on obesity treatment in the UAE

Trial underscores IROS’s commitment to developing innovative therapies for unmet medical needs

Posted in BioUtah News | Tagged | Comments Off on M42’s IROS and Halia Therapeutics launch clinical study on obesity treatment in the UAE

Sethera Therapeutics Completes First Funding Round

Sethera Therapeutics Completes First Funding Round

Posted in BioUtah News | Tagged | Comments Off on Sethera Therapeutics Completes First Funding Round

Sorriso Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results for SOR102 in Ulcerative Colitis

Data from Dual-Acting Oral Biologic Show Promising Safety and Efficacy Profile

Posted in BioUtah News | Tagged | Comments Off on Sorriso Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results for SOR102 in Ulcerative Colitis

CancerVax Passes First Test with Flying Colors

Recent in-vitro lab results confirm that the Company’s Smart mRNA can be used as a potential on/off switch for selectively detecting cancer cells

Posted in BioUtah News | Tagged | Comments Off on CancerVax Passes First Test with Flying Colors

Merit Medical Announces FDA Approval of the WRAPSODY Cell-Impermeable Endoprosthesis

Unique cell-impermeable1 design extends life-saving treatment for dialysis patients.

Posted in BioUtah News | Tagged | Comments Off on Merit Medical Announces FDA Approval of the WRAPSODY Cell-Impermeable Endoprosthesis

Here’s how Utah earned its No. 1 ranking for innovation

A new report from the U.’s Kem C. Gardner Policy Institute uncovers the wide-ranging mechanisms driving Utah’s high performance when it comes to innovation output

Posted in BioUtah News | Comments Off on Here’s how Utah earned its No. 1 ranking for innovation

Teva Announces New Patient Access Program with Direct Relief to Provide Access to Inhalers for Uninsured Patients

Teva to provide two generic inhaler products to Direct Relief for its network of free and charitable clinics. The program, launching this month, will run for a minimum of three years.

Posted in BioUtah News | Tagged | Comments Off on Teva Announces New Patient Access Program with Direct Relief to Provide Access to Inhalers for Uninsured Patients

Myriad Genetics’ RiskScore Study Named One of the Top 10 Significant Advances in Genomic Medicine in American Journal of Human Genetics

Study Demonstrates RiskScore as a More Accurate Predictor of Breast Cancer Risk, Doubling Accuracy Compared to the Tyrer-Cuzick Model

Posted in BioUtah News | Tagged | Comments Off on Myriad Genetics’ RiskScore Study Named One of the Top 10 Significant Advances in Genomic Medicine in American Journal of Human Genetics